Schonfeld Strategic Advisors LLC reduced its position in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 82.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 48,843 shares of the company's stock after selling 229,157 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 0.11% of ESSA Pharma worth $87,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Two Sigma Securities LLC bought a new stake in ESSA Pharma during the 4th quarter valued at $29,000. FNY Investment Advisers LLC bought a new stake in ESSA Pharma during the 4th quarter valued at $44,000. Lepercq Multi Asset Fund bought a new stake in ESSA Pharma during the 4th quarter valued at $54,000. XTX Topco Ltd bought a new stake in ESSA Pharma during the 4th quarter valued at $67,000. Finally, Vazirani Asset Management LLC bought a new stake in ESSA Pharma during the 4th quarter valued at $90,000. 75.12% of the stock is currently owned by institutional investors.
ESSA Pharma Trading Up 3.0%
NASDAQ:EPIX opened at $1.72 on Thursday. The company has a 50-day moving average price of $1.64 and a 200-day moving average price of $1.79. ESSA Pharma Inc. has a 12 month low of $1.40 and a 12 month high of $7.88. The stock has a market cap of $76.35 million, a price-to-earnings ratio of -2.49 and a beta of 1.69.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last posted its earnings results on Thursday, May 8th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. Equities analysts forecast that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.
ESSA Pharma Profile
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
Want to see what other hedge funds are holding EPIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
